Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Assets (2022 - 2025)

Historic Assets for Day One Biopharmaceuticals (DAWN) over the last 4 years, with Q3 2025 value amounting to $513.8 million.

  • Day One Biopharmaceuticals' Assets fell 1448.5% to $513.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $513.8 million, marking a year-over-year decrease of 1448.5%. This contributed to the annual value of $582.8 million for FY2024, which is 5497.7% up from last year.
  • Day One Biopharmaceuticals' Assets amounted to $513.8 million in Q3 2025, which was down 1448.5% from $519.0 million recorded in Q2 2025.
  • Day One Biopharmaceuticals' Assets' 5-year high stood at $600.8 million during Q3 2024, with a 5-year trough of $267.8 million in Q1 2022.
  • For the 4-year period, Day One Biopharmaceuticals' Assets averaged around $429.7 million, with its median value being $404.0 million (2022).
  • The largest annual percentage gain for Day One Biopharmaceuticals' Assets in the last 5 years was 6358.92% (2025), contrasted with its biggest fall of 1448.5% (2025).
  • Quarter analysis of 4 years shows Day One Biopharmaceuticals' Assets stood at $349.1 million in 2022, then rose by 7.73% to $376.0 million in 2023, then soared by 54.98% to $582.8 million in 2024, then dropped by 11.84% to $513.8 million in 2025.
  • Its Assets was $513.8 million in Q3 2025, compared to $519.0 million in Q2 2025 and $534.4 million in Q1 2025.